NCT03502733 will report changes in PD-1, PD-L1, PD-L2, and immune cell profiles and markers of immune-modulation in CLL and low-grade B cell NHL patients with copanlisib and combination ICI. This evidence concerns the gene PDCD1LG2 and B-cell non-Hodgkin lymphoma.